Agilent Technologies Inc (NYSE:A) – Investment analysts at Leerink Swann increased their FY2018 earnings per share estimates for Agilent Technologies in a research note issued on Wednesday, August 15th. Leerink Swann analyst P. Souda now anticipates that the medical research company will post earnings per share of $2.71 for the year, up from their previous estimate of $2.67. Leerink Swann also issued estimates for Agilent Technologies’ Q1 2019 earnings at $0.74 EPS, Q3 2019 earnings at $0.73 EPS, FY2019 earnings at $2.98 EPS, Q1 2020 earnings at $0.80 EPS, Q2 2020 earnings at $0.80 EPS, Q3 2020 earnings at $0.80 EPS and FY2020 earnings at $3.26 EPS.

Agilent Technologies (NYSE:A) last released its earnings results on Tuesday, August 14th. The medical research company reported $0.67 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.04. The firm had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.20 billion. Agilent Technologies had a return on equity of 18.01% and a net margin of 5.02%. The firm’s revenue for the quarter was up 8.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.59 earnings per share.

A number of other brokerages also recently commented on A. ValuEngine downgraded Agilent Technologies from a “buy” rating to a “hold” rating in a research report on Saturday. Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $74.00 price objective for the company in a research report on Tuesday, August 7th. Deutsche Bank increased their price objective on Agilent Technologies from $77.00 to $80.00 and gave the company a “buy” rating in a research report on Wednesday. Cowen upgraded Agilent Technologies from a “market perform” rating to an “outperform” rating in a research report on Tuesday, May 15th. Finally, Morgan Stanley increased their price objective on Agilent Technologies from $83.00 to $84.00 and gave the company an “overweight” rating in a research report on Wednesday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $75.67.

A opened at $64.66 on Thursday. The company has a market capitalization of $21.20 billion, a price-to-earnings ratio of 27.40, a PEG ratio of 2.31 and a beta of 1.29. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.32 and a quick ratio of 2.88. Agilent Technologies has a 1-year low of $60.28 and a 1-year high of $75.00.

In other news, Director Boon Hwee Koh sold 6,931 shares of the stock in a transaction on Tuesday, June 12th. The stock was sold at an average price of $66.38, for a total transaction of $460,079.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Several large investors have recently made changes to their positions in the company. Andra AP fonden raised its stake in Agilent Technologies by 22.0% during the 2nd quarter. Andra AP fonden now owns 94,900 shares of the medical research company’s stock valued at $5,869,000 after purchasing an additional 17,100 shares during the period. Schroder Investment Management Group increased its stake in shares of Agilent Technologies by 21.4% in the second quarter. Schroder Investment Management Group now owns 54,153 shares of the medical research company’s stock worth $3,319,000 after acquiring an additional 9,530 shares during the last quarter. Global X Management Co LLC increased its stake in shares of Agilent Technologies by 31.9% in the second quarter. Global X Management Co LLC now owns 11,889 shares of the medical research company’s stock worth $735,000 after acquiring an additional 2,874 shares during the last quarter. MAI Capital Management acquired a new position in shares of Agilent Technologies in the second quarter worth $394,000. Finally, Verition Fund Management LLC increased its stake in shares of Agilent Technologies by 8.8% in the second quarter. Verition Fund Management LLC now owns 30,175 shares of the medical research company’s stock worth $1,866,000 after acquiring an additional 2,429 shares during the last quarter.

About Agilent Technologies

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.

Featured Story: What does RSI mean?

Earnings History and Estimates for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.